We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mutation Boosts Cholesterol Clearance

By Biotechdaily staff writers
Posted on 20 Apr 2005
Researchers working with a mouse model have found that disabling the gene coding for the PCSK9 protein (proprotein convertase subtilisin/kexin type 9a) slowed the degradation of low-density lipoprotein receptors (LDLr) from liver cells, which caused a dramatic decrease in levels of LDL in the blood.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA; www.utsouthwestern.edu) genetically engineered a line of "knockout” mice lacking the gene for PCSK9. More...
They reported in the April 1, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences that the livers of these mice had increased LDLr protein but not messenger RNA (mRNA). The additional LDLr protein led to greater clearance of circulating lipoproteins and decreased plasma cholesterol levels (46 mg/dl in the knockout- mice versus 96 mg/dl in control animals). These findings complement earlier reports that humans with mutations that disabled the PCSK9 gene had LDL cholesterol levels 40% lower than individuals without the mutation.

"The expression of LDL receptors is the primary mechanism by which humans lower LDL cholesterol in the blood,” said senior author Dr. Jay Horton, associate professor of internal medicine and molecular genetics at the University of Texas Southwestern Medical Center. "This research shows that in mice, deleting the PCSK9 protein results in an increase in LDL receptors and a significant lowering of LDL cholesterol. The lower cholesterol levels of humans with mutations in PCSK9, combined with the results of our studies in mice, suggest that variations in the levels of the PCSK9 protein significantly affect blood cholesterol levels, and compounds that inhibit this protein may be useful for the treatment of high cholesterol.”




Related Links:
University of Texas Southwestern Medical Center

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Repetitive Pipette
VWR® Stepper Pro
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.